Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data

Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data

  • April 30, 2026

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating five clinical trials in the process.

Leave A Comment

Fields (*) Mark are Required